Coronary and cardiovascular risk estimation for primary prevention:validation of a new Sheffield table in the 1995 Scottish health survey population
====================================================================================================================================================

* Erica J Wallis
* Lawrence E Ramsay
* Iftikhar UI Haq
* Parviz Ghahramani
* Peter R Jackson
* Karen Rowland Yeo
* Wilfred W Yeo

## Abstract

**Objective:** To examine the accuracy of a new version of the Sheffield table designed to aid decisions on lipids screening and detect thresholds for risk of coronary heart disease needed to implement current guidelines for primary prevention of cardiovascular disease.

**Design:** Comparison of decisions made on the basis of the table with absolute risk of coronary heart disease or cardiovascular disease calculated by the Framingham risk function. The decisions related to statin treatment when coronary risk is ≥years; aspirin treatment when the risk is ≥ 15% over 10 years; and the treatment of mild hypertension when the cardiovascular risk is≥0% over 10 years.

**Setting:** The table is designed for use in general practice.

**Subjects:** Random sample of 1000 people aged 35–64 years from the 1995 Scottish health survey.

**Main outcome measures:** Sensitivity, specificity, and positive and negative predictive values of the table.

**Results:** 13% of people had a coronary risk of ≥15%, and 2.2% a risk of ≥30%, over 10 years. 22% had mild hypertension (systolic blood pressure 140–159 mm Hg). The table indicated lipids screening for everyone with a coronary risk of ≥15% over 10 years, for 95% of people with a ratio of total cholesterol to high density lipoprotein cholesterol of ≥8.0, but for <50% with a coronary risk of <5% over 10 years. Sensitivity and specificity were 97% and 95% respectively for a coronary risk of ≥15% over 10 years; 82% and 99% for a coronary risk of ≥30% over 10 years; and 88% and 90% for a cardiovascular risk of ≥20% over 10 years in mild hypertension.

**Conclusion:** The table identifies all high risk people for lipids screening, reduces screening of low risk people by more than half, and ensures that treatments are prescribed appropriately to those at high risk, while avoiding inappropriate treatment of people at low risk.

*Editorial by Jackson*

## Introduction

When hydroxymethyl glutaryl coenzyme A (HMG Co-A) reductase inhibitors (statins), antihypertensive drugs, and aspirin are used for primary prevention of coronary heart disease or cardiovascular disease, the absolute risk determines benefit to the individual, cost effectiveness, proportion of the population treated, and the total cost of treatment.1–5 Joint guidelines by four British societies6 and British Hypertension Society guidelines7 recommend aspirin and treatment of mild hypertension when a risk of coronary heart disease is 15% over 10 years. For hypertension treatment this risk is considered equivalent to a risk of cardiovascular disease of 20% over 10 years.7 Statins are also justified when coronary risk is 15% over 10 years, but because of resource implications the guidelines recommend treatment when coronary risk is ≥30% over 10 years as a priority, with treatment when coronary risk is 15% to be given when and where resources permit.67 Absolute coronary risk relates only weakly to single risk factors such as blood pressure or lipid concentrations, and it is estimated best by counting and weighting major coronary risk factors using risk functions derived from epidemiological studies.89

Several risk assessment methods based on the Framingham risk function, 36 10–12 including the Sheffield table, 1314 are widely used. We modified the Sheffield table to identify coronary risk thresholds specified in the new guidelines—namely, 15% and 30% over 10 years—and to improve accuracy we based it on the ratio of total cholesterol to high density lipoprotein cholesterol (TC:HDL ratio) rather than on cholesterol concentration alone.15 We report the accuracy of this table for identifying risk of coronary heart disease of 15% and 30% over 10 years in a general population; examine whether coronary risk of 15% over 10 years is an acceptable surrogate for cardiovascular risk of 20% over 10 years in mild hypertension; and evaluate the table as a tool for selective lipids screening.

#### Definitions of heart disease

*   Coronary heart disease is defined as a fatal or non-fatal myocardial infarction plus incident angina

*   Cardiovascular disease is defined as coronary heart disease but also including stroke, peripheral vascular disease, and heart failure

![Fig 1.](http://www.bmj.com/https://www.bmj.com/content/bmj/320/7236/671/F1.medium.gif)

[Fig 1.](http://www.bmj.com/content/320/7236/671/F1)

Fig 1. 
New Sheffield table

**Note:** This table was amended on 29 March to correct five values of the total:HDL cholesterol ratio that were wrong in the originally published table. The revised values are those for men aged 40, 38, 36, 34, and 32 years in the yellow column (15%) furthest to the left. A written correction will appear in a subsequent issue of the BMJ.

## Methods

### Sheffield table

The Sheffield table was constructed by using the Framingham function8 to compute TC:HDL ratios conferring coronary risks of 15% and 30% over 10 years from age, sex, smoking, diabetes, and systolic blood pressure. The upper limit for the TC:HDL ratio was set at three standard deviations above the population mean. As before, systolic blood pressure was dichotomised to 160 mm Hg for those with “hypertension” and 139 mm Hg for “no hypertension.” The table and instructions (fig 1) are designed as a one page guide to screening, assessment of coronary risk, treatment with aspirin and statins, and treatment for mild hypertension according to current guidelines.6 7

### Population data

The 1995 Scottish health survey is a cross sectional survey of a stratified random sample of the Scottish population aged 35–64 years.16 From 4910 people screened we excluded those with no lipids measurement (946); requiring secondary prevention (339); with incomplete data (549); and taking lipid lowering drugs (19). From the 3057 people with complete data we studied a random sample of 1000 people representative of those aged 35–64 years in the Scottish population who might require primary prevention. Using age, sex, blood pressure, smoking habit, diabetes status, and TC:HDL ratio and assuming absence of left ventricular hypertrophy, we calculated coronary and cardiovascular risks for each individual using the Framingham function.

### Risk assessment with table

Seven doctors who were blind to calculated risk estimates used the new table to carry out risk assessments. Each of the 1000 people had their coronary risk assessed by two different doctors; thus each doctor assessed two sevenths of the population sample. Each doctor was given the person's age, sex, blood pressure, smoking habit, diabetes status, and TC:HDL ratio and recorded three decisions: *(a)* was measurement of the TC:HDL ratio indicated? (*b)* was coronary risk ≥15% over 10 years? and *(c)* was coronary risk ≥30% over 10 years? There were seven errors in 6000 decisions (0.1%); error rates for all seven assessors were between 0% and 0.7%. These errors were reconciled for final decisions by the table.

### Statistical analysis

Using Framingham estimates of coronary heart disease as the gold standard, we calculated the sensitivity, specificity, and predictive values with 95% confidence intervals for the table for coronary risks of 15% and 30% over 10 years. In the people with mild hypertension (systolic blood pressure 140–159 mm Hg) we examined the accuracy of coronary risk of 15% over 10 years for predicting cardiovascular risk of 20% over 10 years.

## Results

### Population

Of the 1000 people studied 56.2% (562) were women; 29.9% (299) smoked; and 1.6%16 were diabetic. The mean age was 49 years; mean blood pressure was 132/75 mm Hg; mean cholesterol concentration was 6.0 mmol/l;mean high density lipoprotein cholesterol was 1.45 mmol/l; and the mean TC:HDL ratio was 4.5. Altogether, 21.7% (217) of people had mild hypertension, and 7.0% (70) had systolic blood pressure of≥160 mm Hg. Mean 10 year coronary and cardiovascular risks according to the Framingham risk function were 7.2% and 10.4% respectively, and the 10 year coronary risk was ≥15% in 13.3% (133) of people and ≥30% in 2.2% (22).

### Accuracy for coronary and cardiovascular risk thresholds

The Sheffield table had 97% sensitivity and 95% specificity for coronary risk of ≥15% over 10 years. The predictive value of a negative test was 99.5% and of a positive test 73%, with all those with false positive results having a coronary risk of 10.0-15.0% over 10 years (fig 2). For coronary risk of ≥30% over 10 years the sensitivity was 82% and the specificity 99% (table 1). False negative results were all only marginally above the 30% threshold, and those with false positive results all had coronary risk of ≥20% over 10 years (fig 2). In those with systolic blood pressure of 140–159 mm Hg, coronary risk of ≥15% over 10 years according to the table had 88% sensitivity and 90% specificity for predicting cardiovascular risk ≥20% over 10 years (table 1). Those classified incorrectly all lay close to the 20% threshold.

![Fig 2.](http://www.bmj.com/https://www.bmj.com/content/bmj/320/7236/671/F2.medium.gif)

[Fig 2.](http://www.bmj.com/content/320/7236/671/F2)

Fig 2. 
Accuracy of new Sheffield table for predicting risk of coronary heart disease of 15% over 10 years and 30% over 10 years in 1000 people assessed for primary prevention. For the 15% threshold, sensitivity was 97% and specificity 95%; for the 30% threshold, sensitivity was 82% and specificity 99%

View this table:
[Table 1.](http://www.bmj.com/content/320/7236/671/T1)

Table 1. 
Sensitivity, specificity, and positive and negative predictive values (95% confidence intervals) for new Sheffield table in predicting risk of coronary heart disease of 15% and 30% over 10 years in 1000 people, and risk of cardiovascular disease of 20% over 10 years in mild hypertension (systolic blood pressure 140–159 mm Hg)

### Screening on basis of Sheffield table

According to this table, lipids would have been measured in 70% of this population (in 100% with coronary risk of >= 15%, in 97% with coronary risk of 5.0-14.9%, and in 46% with coronary risk <5% over 10 years). The proportion of people who would have been screened was higher in men than in women and increased with age (from 61% of men and 11% of women aged 35-44; to 100% of men and women aged 55–64 years) (fig 3). The proportion of people screened increased as the TC:HDL ratio increased (table 2). This reflects clustering of hyperlipidaemia with other risk factors and is not a specific function of the table. The screening rate in people with a TC:HDL ratio of >= 8.0 was high (94%), so that only two people above this level would not have been screened, unless a family history of hyperlipidaemia was suspected (see notes in figure 1).

View this table:
[Table 2.](http://www.bmj.com/content/320/7236/671/T2)

Table 2. 
Proportion of 1000 people in whom measurement of ratio of total cholesterol to high density lipoprotein cholesterol (TC:HDL ratio) was indicated, according to new Sheffield table

![Fig 3.](http://www.bmj.com/https://www.bmj.com/content/bmj/320/7236/671/F3.medium.gif)

[Fig 3.](http://www.bmj.com/content/320/7236/671/F3)

Fig 3. 
Pattern of lipids screening in population, according to age and sex, if new Sheffield table had been used for decisions on screening (error bars are 95% confidence intervals)

## Discussion

### Accuracy of table

The table identified correctly 97% of those with a risk of coronary heart disease of ≥15% over 10 years; these people might require treatment with aspirin and (where resources permit) statins for primary prevention.6 High risk people not identified were only marginally above the 15% threshold, and decisions that coronary risk was below 15% over 10 years were 99.5% correct. The table incorrectly identified for treatment 5% of people with coronary risk below 15% over 10 years, but all had coronary risks of 10-15%, which is a risk level at which statin treatment is safe.17 No one with very low risk was identified for treatment.

Current guidelines recommend that, because of resource constraints, statin treatment should be given as a priority to people whose coronary risk is ≥30% over 10 years.6 7 18 The table identified correctly 82% of those at such a risk, with those not identified for treatment only marginally above the threshold. One per cent of the population were identified incorrectly as having coronary risk ≥30% over 10 years, but all of these had a risk of 20-30%. Coronary risk increases with age, and the table can be used to look forward in time. Analyses of sensitivity and specificity ignore this and underestimate the information provided by the table.

### Dichotomising blood pressure

Most Framingham based risk methods offer a wide range of blood pressures3–12 and seem more accurate than this table, but our results indicate that little accuracy is sacrificed by dichotomising blood pressure, even when uncontrolled hypertension is ignored. The table is designed for use only after the control of moderate to severe hypertension, with assessment for aspirin and statins postponed until this is achieved. False negatives would not have occurred had it been used in this way. The apparent accuracy for blood pressure offered by other methods is misleading. In people whose hypertension has been treated, pretreatment blood pressure overestimates long term risk, 19 whereas blood pressure taken while a person is taking treatment underestimates the risk because the risk remains higher than is predicted during treatment.19 20 The Sheffield table assumes that coronary risk assessment is done after hypertension has been controlled, and it approximates the persistently increased coronary risk in people receiving treatment by using systolic blood pressure 160 mm Hg for risk calculation.

Treatment decisions for uncomplicated mild hypertension are best guided by risk assessment, 3 4 but it is counterintuitive to target coronary rather than cardiovascular risk because antihypertensive treatment causes larger reductions in stroke (38%) than in coronary heart disease (16%).19 However, the 15% coronary risk threshold predicted cardiovascular risk of ≥20% over 10 years in people with mild hypertension, with 88% sensitivity and 90% specificity.

### Use of table as screening tool

In the United Kingdom selective lipids measurement in those at high risk has been preferred to population screening, but this may need reappraisal, given new evidence for the statins. The Sheffield table identified for screening everyone with a coronary risk of ≥15% over 10 years without the need for general screening. Everyone aged ≥55 years, and almost everyone aged 45-54, needed screening. Savings from selective screening will be attained only in younger people. At age 35–44 years, 65% of people (39% of men, 89% of women) need not be screened, and few people aged under 35 would be screened. Selective screening may miss some people with extremely high lipid concentrations resulting from familial hyperlipidaemia; the Sheffield table, however, detected most people with severe hyperlipidaemia because screening aimed at those with high coronary risk coincidentally also reaches those with high lipid concentrations. Among 1000 people, only two with a ratio of total cholesterol to high density lipoprotein cholesterol of ≥8.0 were missed; they had ratios of 12.4 and 12.6 and would generally be treated with a statin if detected. Unless diagnosed through their family history, detection would require additional routine screening of 297 people not otherwise screened, including 65% of people aged 35–44 years. The value of detecting these relatively uncommon individuals needs to be weighed against the additional cost, resources, and harm from “labelling” (when “well” people become “patients”) as a result of general screening.

### Targeting treatment at absolute risk

Compared with decisions based on blood pressure or lipids thresholds alone, methods that entail simple counting of risk factors21–23 improve the accuracy of risk assessment significantly9 yet still identify for treatment some people at very low risk15 who may be harmed by treatment with, for example, aspirin, while failing to treat some with exceptionally high risk. Framingham based methods are a step towards ensuring that those at high risk get treatment and those at low risk are not endangered. The Framingham estimates of coronary risk seem acceptably accurate for the British population, 24 but additional risk factors, such as left ventricular hypertrophy, family history, familial hyperlipidaemia, and ethnic status, influence coronary risk (see notes in figure 1). Framingham based methods should therefore guide but not dictate treatment decisions. The Sheffield table identifies those who definitely should be offered treatments, but it should not be used to deny treatment to people close to treatment thresholds.

#### What is already known on this topic

New guidelines for prescribing of statins, aspirin, and treatment of mild hypertension for primary prevention recommend targeting treatment according to absolute risk of coronary heart disease

Doctors need simple but accurate methods for estimating such risk

#### What this study adds

A new Sheffield table has been developed to identify the coronary risk thresholds in current guidelines

In a random sample of the population aged 35–64 years without atherosclerotic disease, estimates of coronary risk by this table were accurate when compared with coronary risk calculated using the Framingham risk function

The sensitivity and specificity values were high for coronary risk of >= 15% over 10 years, coronary risk of>= 30% over 10 years, and cardiovascular risk of >= 20% over 10 years in mild hypertension

Numerous Framingham based risk assessment methods are available.3 6 10–14 Computer based methods 6 12 provide absolute coronary risks accurately, and also relative risk, stroke risk, and the effects of interventions.12 However, doctors need to identify and manage about 13% of adults for primary prevention, plus 5% for secondary prevention, 1 and this level of sophistication may not be necessary or even helpful. Among paper based methods, those based on the ratio of total cholesterol to high density lipoprotein cholesterol 3 6 are more accurate than those based on total cholesterol concentration alone.10 13 14 Methods for assessing coronary risk6 rather than cardiovascular risk3 are better suited to British and European guidelines, which target coronary risk thresholds.6 10 The chart produced jointly by British societies6 and the Sheffield table described here are similar in principle and policy. The British societies' chart offers one additional coronary risk level (20% over 10 years) and apparent accuracy for blood pressure, but lower accuracy for the ratio of total cholesterol to high density lipoprotein cholesterol and for age. The Sheffield table is more compact and is designed as a one page guideline in addition to its risk assessment function. It is unique among paper based methods in offering an explicit screening function that allows doctors to adopt an accurate selective policy for lipids screening.

## Acknowledgments

We thank Phil Sanmuganathan and Rod Williamson, who performed risk assessments, and the original depositors and data archive for access to data from the Scottish health survey 1995. Those who conducted the survey and the original analysis of the data bear no responsibility for their further analysis or interpretation. We acknowledge Crown copyright material (data collected in the Scottish health survey) reproduced by permission of the controller of HMSO.

Contributors: All authors contributed to the design of the study, development of the table, risk assessments, writing of the manuscript, and approval of the final version. IUH generated the Sheffield table from the Framingham equation. EJW coordinated development of the format of the table. IUH and EJW prepared the population data. KRY prepared study materials and coordinated the risk assessments. PG and PRJ performed the statistical analysis. LER designed the study, drafted the manuscript, and will act as guarantor for the study.

## Footnotes

*   Funding None

*   Competing interests None declared

## References

1.  1.Haq IU, Ramsay LE, Pickin DM, Yeo WW, Jackson PR, Payne JN. Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci 1996; 91: 399–413.
    
    [PubMed](http://www.bmj.com/lookup/external-ref?access_num=8983865&link_type=MED&atom=%2Fbmj%2F320%2F7236%2F671.atom) 

2.  2.Pickin DM, McCabe CJ, Ramsay LE, Payne N, Haq IU, Yeo WW, et al. Cost-effectiveness of HMG CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment Heart 1999; 82: 325–332.
    
    [Abstract/FREE Full Text](http://www.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiaGVhcnRqbmwiO3M6NToicmVzaWQiO3M6ODoiODIvMy8zMjUiO3M6NDoiYXRvbSI7czoyMjoiL2Jtai8zMjAvNzIzNi82NzEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

3.  3.Core Services Committee, Ministry of Health. Ministry of Health guidelines for the management of mildly raised blood pressure in New Zealand. Wellington: Ministry of Health, 1995.
    
    

4.  4.Ramsay LE, Wallis EJ, Yeo WW, Jackson PR. The rationale for differing national recommendations for the treatment of hypertension. Am J Hypertens 1998; 11: 79–88S.
    
    

5.  5.Boissel JP. Individualizing aspirin therapy for prevention of cardiovascular events. JAMA 1998; 280: 1949–1950.
    
    [CrossRef](http://www.bmj.com/lookup/external-ref?access_num=10.1001/jama.280.22.1949&link_type=DOI) 
    
    [PubMed](http://www.bmj.com/lookup/external-ref?access_num=9851483&link_type=MED&atom=%2Fbmj%2F320%2F7236%2F671.atom) 
    
    [Web of Science](http://www.bmj.com/lookup/external-ref?access_num=000077364500042&link_type=ISI) 

6.  6.Wood D, Durrington P, Poulter N, McInnes G, Rees A, Wray R, on behalf of the British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society and endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80(suppl 2): S1–29.
    
    [FREE Full Text](http://www.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiaGVhcnRqbmwiO3M6NToicmVzaWQiO3M6MTM6IjgwL3N1cHBsXzIvUzEiO3M6NDoiYXRvbSI7czoyMjoiL2Jtai8zMjAvNzIzNi82NzEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

7.  7.Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999; 319: 630–635.
    
    [FREE Full Text](http://www.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjEyOiIzMTkvNzIxMC82MzAiO3M6NDoiYXRvbSI7czoyMjoiL2Jtai8zMjAvNzIzNi82NzEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

8.  8.Anderson KM, Odel PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293–298.
    
    [CrossRef](http://www.bmj.com/lookup/external-ref?access_num=10.1016/0002-8703(91)90861-B&link_type=DOI) 
    
    [PubMed](http://www.bmj.com/lookup/external-ref?access_num=1985385&link_type=MED&atom=%2Fbmj%2F320%2F7236%2F671.atom) 
    
    [Web of Science](http://www.bmj.com/lookup/external-ref?access_num=A1991EQ99500009&link_type=ISI) 

9.  9.Grover SA, Coupal L, Hu X-P. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995; 274: 801–806.
    
    [CrossRef](http://www.bmj.com/lookup/external-ref?access_num=10.1001/jama.1995.03530100041032&link_type=DOI) 
    
    [PubMed](http://www.bmj.com/lookup/external-ref?access_num=7650803&link_type=MED&atom=%2Fbmj%2F320%2F7236%2F671.atom) 
    
    [Web of Science](http://www.bmj.com/lookup/external-ref?access_num=A1995RU32400027&link_type=ISI) 

10. 10.Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Eur Heart J 1998; 19: 1434–1503.
    
    [FREE Full Text](http://www.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6MzoiUERGIjtzOjExOiJqb3VybmFsQ29kZSI7czozOiJlaGoiO3M6NToicmVzaWQiO3M6MTA6IjE5LzEwLzE0MzQiO3M6NDoiYXRvbSI7czoyMjoiL2Jtai8zMjAvNzIzNi82NzEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

11. 11.Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847.
    
    [Abstract/FREE Full Text](http://www.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTQ6ImNpcmN1bGF0aW9uYWhhIjtzOjU6InJlc2lkIjtzOjEwOiI5Ny8xOC8xODM3IjtzOjQ6ImF0b20iO3M6MjI6Ii9ibWovMzIwLzcyMzYvNjcxLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

12. 12.Hingorani AD, Vallance P. A simple computer program for guiding management of cardiovascular risk factors and prescribing. BMJ 1999; 318: 101–105.
    
    [Abstract/FREE Full Text](http://www.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjEyOiIzMTgvNzE3Ni8xMDEiO3M6NDoiYXRvbSI7czoyMjoiL2Jtai8zMjAvNzIzNi82NzEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

13. 13.Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995; 346: 1467–1471.
    
    [CrossRef](http://www.bmj.com/lookup/external-ref?access_num=10.1016/S0140-6736(95)92477-9&link_type=DOI) 
    
    [PubMed](http://www.bmj.com/lookup/external-ref?access_num=7490996&link_type=MED&atom=%2Fbmj%2F320%2F7236%2F671.atom) 
    
    [Web of Science](http://www.bmj.com/lookup/external-ref?access_num=A1995TH15600014&link_type=ISI) 

14. 14.Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996; 348: 387–388.
    
    [CrossRef](http://www.bmj.com/lookup/external-ref?access_num=10.1016/S0140-6736(96)05516-X&link_type=DOI) 
    
    [PubMed](http://www.bmj.com/lookup/external-ref?access_num=8709740&link_type=MED&atom=%2Fbmj%2F320%2F7236%2F671.atom) 
    
    [Web of Science](http://www.bmj.com/lookup/external-ref?access_num=A1996VB42600016&link_type=ISI) 

15. 15.Haq IU, Ramsay LE, Jackson PR, Wallis EJ. Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methods. Q J Med 1999; 92: 379–385.
    
    [Abstract/FREE Full Text](http://www.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NToicWptZWQiO3M6NToicmVzaWQiO3M6ODoiOTIvNy8zNzkiO3M6NDoiYXRvbSI7czoyMjoiL2Jtai8zMjAvNzIzNi82NzEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

16. 16.Joint Health Surveys Unit of Social and Community Planning Research and University College London. Scottish health survey. Colchester: University of Essex, 1995 (computer file, 2nd ed). (The Data Archive (distributor), 30 November 1998. SN;3807)
    
    

17. 17.Downs GR, Clearfield M, Weiss S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–1622.
    
    [CrossRef](http://www.bmj.com/lookup/external-ref?access_num=10.1001/jama.279.20.1615&link_type=DOI) 
    
    [PubMed](http://www.bmj.com/lookup/external-ref?access_num=9613910&link_type=MED&atom=%2Fbmj%2F320%2F7236%2F671.atom) 
    
    [Web of Science](http://www.bmj.com/lookup/external-ref?access_num=000073758600030&link_type=ISI) 

18. 18.Standing Medical Advisory Committee. The use of statins. London: Department of Health, 1997. (11061 HCD Aug 97(04))
    
    

19. 19.1.  Swales JD
    
    Collins R, Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales JD, ed. Textbook of hypertension. Oxford: Blackwell Scientific, 1992: 1156–1164.
    
    

20. 20.Sytkowski PA, D'Agostino RB, Huse DM, Russell MW, Hartz SC. New coronary risk functions for pharmacologically treated hypertensives: the Framingham heart study. Circulation 1997; 96(suppl I): 437.
    
    

21. 21.Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, the National High Blood Pressure Education Program Coordinating Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1998; 157: 2413–2446.
    
    

22. 22.National Cholesterol Education Programme. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation 1994; 89: 1333–1345.
    
    [CrossRef](http://www.bmj.com/lookup/external-ref?access_num=10.1161/01.CIR.89.3.1333&link_type=DOI) 
    
    [PubMed](http://www.bmj.com/lookup/external-ref?access_num=8124825&link_type=MED&atom=%2Fbmj%2F320%2F7236%2F671.atom) 

23. 23.Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151–183.
    
    [PubMed](http://www.bmj.com/lookup/external-ref?access_num=10067786&link_type=MED&atom=%2Fbmj%2F320%2F7236%2F671.atom) 
    
    [Web of Science](http://www.bmj.com/lookup/external-ref?access_num=000079235700001&link_type=ISI) 

24. 24.Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999; 81: 40–46.
    
    [Abstract/FREE Full Text](http://www.bmj.com/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiaGVhcnRqbmwiO3M6NToicmVzaWQiO3M6NzoiODEvMS80MCI7czo0OiJhdG9tIjtzOjIyOiIvYm1qLzMyMC83MjM2LzY3MS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=)